AtheroGenics (AGIX) tumbled nearly 60% early Monday after the company said a Phase III clinical study of its lead drug candidate failed to reach its primary endpoint, showing no difference when compared with a placebo.
Shares sank $4.58 to $3.25 recently. The company said even though AGI-1067 missed its main target, it did meet a number of other important predefined endpoints. These included a reduction in the composite of "hard" atherosclerotic clinical endpoints, composed of cardiovascular death, heart attack and stroke, as well as an improvement in several key diabetes parameters, including glycemic control. Despite the setback, AtheroGenics plans to continue to pursue opportunities for the development of AGI-1067. AtheroGenics and AstraZeneca (AZN) have a worldwide collaboration covering the development and commercialization of the drug. After the final analysis of the study results is completed, AstraZeneca will have 45 days to decide whether to continue with the arrangement.>To order reprints of this article, click here: ReprintsTheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,759.53 | 1,337.45 | 2,898.07 | 19.86 |
Oil *
117.16
|
|
DOWN
130.93 |
DOWN
14.50 |
DOWN
29.16 |
DOWN
0.61 |
10 Yr
1.99%
SPDR Gold
166.72
|
|
-1.02%
|
-1.07%
|
-1.00%
|
-2.98%
|
Data delayed 20 minutes |
Connect with TheStreet